ClinicaliQ Trial Snapshot
- A Study of ZL-1310 Versus Investigator’s Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) — Recruiting • Phase III • Oncology • NCT07218146.
- What is being tested: ZL-1310, a novel therapeutic agent, is being compared against standard investigator-selected treatments in patients with relapsed small cell lung cancer (SCLC) to evaluate its efficacy and safety profile.
- Patient eligibility overview: The trial enrolls patients with relapsed small cell lung cancer; eligibility criteria typically include confirmed SCLC diagnosis, prior treatment exposure, adequate organ function, and performance status meeting study requirements.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Eligibility Snapshot
- : * Age >/= 18 years, or considered an adult by local regulations, at the time of consent * Signed informed consent * Histologically or cytologically confirmed SCLC. Received 1L platinum-based systemic therapy and had documented disease progression during or after the most recent systemic therapy. Or received 2L tarlatamab is allowed. * Measurable disease according to RECIST v1.1 as assessed by the investigator. * Participants with a history of treated and stable or untreated and asymptomatic CNS metastases based on criteria per protocol. * Adequate organ and marrow function * Eastern Cooperative Group (ECOG) performance status of 0 or 1 * Life expectancy of at least 3 months * Participants must be willing to undergo a tumor biopsy or provide archived tumor tissue sample at Screening * Participants must be willing and able to comply with protocol for the duration of the study
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.